SK5102002A3 - Oral formulations for anti-tumor compounds - Google Patents

Oral formulations for anti-tumor compounds Download PDF

Info

Publication number
SK5102002A3
SK5102002A3 SK510-2002A SK5102002A SK5102002A3 SK 5102002 A3 SK5102002 A3 SK 5102002A3 SK 5102002 A SK5102002 A SK 5102002A SK 5102002 A3 SK5102002 A3 SK 5102002A3
Authority
SK
Slovakia
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
lecithin
cpt
composition according
Prior art date
Application number
SK510-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Lorena Muggetti
Alessandro Martini
Paola Civaroli
Christopher James
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of SK5102002A3 publication Critical patent/SK5102002A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK510-2002A 1999-10-22 2000-10-02 Oral formulations for anti-tumor compounds SK5102002A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9925127.4A GB9925127D0 (en) 1999-10-22 1999-10-22 Oral formulations for anti-tumor compounds
PCT/EP2000/009647 WO2001030351A1 (en) 1999-10-22 2000-10-02 Oral formulations for anti-tumor compounds

Publications (1)

Publication Number Publication Date
SK5102002A3 true SK5102002A3 (en) 2002-11-06

Family

ID=10863264

Family Applications (1)

Application Number Title Priority Date Filing Date
SK510-2002A SK5102002A3 (en) 1999-10-22 2000-10-02 Oral formulations for anti-tumor compounds

Country Status (26)

Country Link
US (1) US7201913B1 (ja)
EP (1) EP1223936A1 (ja)
JP (1) JP2003512430A (ja)
KR (1) KR100838097B1 (ja)
CN (1) CN1198616C (ja)
AR (1) AR031834A1 (ja)
AU (1) AU784201B2 (ja)
BR (1) BR0014902A (ja)
CA (1) CA2387648A1 (ja)
CO (1) CO5251471A1 (ja)
CZ (1) CZ20021372A3 (ja)
EA (1) EA008284B1 (ja)
GB (1) GB9925127D0 (ja)
HK (1) HK1048253B (ja)
HU (1) HUP0202850A3 (ja)
IL (2) IL149044A0 (ja)
MX (1) MXPA02003904A (ja)
MY (1) MY138106A (ja)
NO (1) NO322782B1 (ja)
NZ (1) NZ518398A (ja)
PE (1) PE20010809A1 (ja)
PL (1) PL356236A1 (ja)
SK (1) SK5102002A3 (ja)
TW (1) TWI233355B (ja)
WO (1) WO2001030351A1 (ja)
ZA (1) ZA200203042B (ja)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0300848A3 (en) 2000-02-28 2005-03-29 Aventis Pharma Sa A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
ITRM20030074A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Formulazioni semisolide a rilascio immediato intese
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
US20070053869A1 (en) * 2005-09-02 2007-03-08 Yuichi Sugiyama Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
CN101621997B (zh) 2007-01-26 2013-05-08 株式会社宝丽制药 医药组合物
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200920347A (en) * 2007-07-16 2009-05-16 Poniard Pharmaceuticals Inc Oral formulations for picoplatin
EP2249644A4 (en) * 2008-02-08 2012-05-30 Poniard Pharmaceuticals Inc PICOPLATIN AND AMRUBICIN USEFUL IN THE TREATMENT OF LUNG CANCER
HUP0900614A2 (en) * 2009-09-29 2011-05-30 Mate Dr Hidvegi Preparation comprising dehydrated, fermented material with amorphous crystaline structure and process for its production
WO2011071194A1 (ko) * 2009-12-08 2011-06-16 주식회사 일화 20-O-β-D-글루코피라노실-20(S)-프로토파낙사디올을 포함하는 고체분산체
WO2014123899A1 (en) 2013-02-05 2014-08-14 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
KR102537085B1 (ko) * 2014-01-17 2023-05-25 옹코랄 파르마 에이피에스 암의 치료를 위한 이리노테칸의 고형 경구 투여형
CN110448533B (zh) * 2014-12-05 2022-03-29 天津键凯科技有限公司 一种聚乙二醇修饰的喜树碱类衍生物的药物组合物及其制备方法
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
KR102185475B1 (ko) 2019-06-20 2020-12-02 대화제약 주식회사 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2031803C (en) * 1989-12-13 2001-05-29 Ramakrishnan Nagarajan Improvements in or relating to glycopeptide deriveratives
US5552156A (en) 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5433951A (en) 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
IL115099A (en) 1994-10-14 1999-04-11 Upjohn Co Lyophilizate of phospholipid complex of water insoluble camptothecins
IL139728A (en) * 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
US5954998A (en) * 1995-05-25 1999-09-21 The Clorox Company Liquid peracid precursor colloidal dispersions: oil-core vesicles
ATE554750T1 (de) * 1997-03-05 2012-05-15 Sugen Inc Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
GB9711962D0 (en) * 1997-06-10 1997-08-06 Reckitt & Colmann Prod Ltd Therapeutically active compositions
CA2294032A1 (en) * 1997-07-29 1999-02-11 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
AR013261A1 (es) * 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
US6573290B1 (en) * 1999-05-17 2003-06-03 Ilex Oncology, Inc. DFMO and celecoxib in combination for cancer chemoprevention and therapy
GB9918885D0 (en) * 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules

Also Published As

Publication number Publication date
CZ20021372A3 (cs) 2002-09-11
EP1223936A1 (en) 2002-07-24
ZA200203042B (en) 2003-04-17
JP2003512430A (ja) 2003-04-02
HUP0202850A3 (en) 2004-12-28
IL149044A0 (en) 2002-11-10
MY138106A (en) 2009-04-30
GB9925127D0 (en) 1999-12-22
CA2387648A1 (en) 2001-05-03
MXPA02003904A (es) 2003-07-14
CO5251471A1 (es) 2003-02-28
NO322782B1 (no) 2006-12-11
KR20020045613A (ko) 2002-06-19
KR100838097B1 (ko) 2008-06-13
HUP0202850A2 (hu) 2003-01-28
CN1198616C (zh) 2005-04-27
NO20021834D0 (no) 2002-04-18
EA008284B1 (ru) 2007-04-27
NO20021834L (no) 2002-04-18
AU784201B2 (en) 2006-02-23
NZ518398A (en) 2004-01-30
AU7661300A (en) 2001-05-08
US7201913B1 (en) 2007-04-10
HK1048253B (zh) 2005-12-02
BR0014902A (pt) 2002-06-11
HK1048253A1 (en) 2003-03-28
TWI233355B (en) 2005-06-01
IL149044A (en) 2007-03-08
CN1382050A (zh) 2002-11-27
PL356236A1 (en) 2004-06-28
AR031834A1 (es) 2003-10-08
WO2001030351A1 (en) 2001-05-03
PE20010809A1 (es) 2001-08-01
EA200200480A1 (ru) 2002-10-31

Similar Documents

Publication Publication Date Title
SK5102002A3 (en) Oral formulations for anti-tumor compounds
AU762926B2 (en) Methods and compositions for delivery of taxanes
CN101287466B (zh) 用于改善7-[(e)-叔丁氧亚氨基甲基]喜树碱经口吸收的即释治疗系统
EA006550B1 (ru) Фармацевтическая композиция на основе микронизированного прогестерона, способ её получения и её применение
CA2354039C (en) Pharmaceutical formulations in hydroxypropylmethylcellulose capsules
KR20240100433A (ko) 암의 치료에 유용한 면역원성 세포 사멸 (icd) 유도 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 나노담체 조성물 및 그의 방법
CN101601642A (zh) 一种囊泡类给药系统及其应用
EP4140480A1 (en) Drug combination and use thereof
CN108066311B (zh) 一种吉马替康胶囊及其制备方法
PL206522B1 (pl) Kompozycja farmaceutyczna zawierająca winorelbinę w miękkich kapsułkach i jej zastosowanie
JP7492977B2 (ja) イリノテカン遊離塩基を含む経口投与用の医薬組成物
CN107510652A (zh) 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法
WO2022204757A1 (en) Improved isoflavone formulation
KR20240053626A (ko) 강화된 sn-38 용해성 및 경구 흡수성을 갖는 제형
US20060094692A1 (en) Pharmaceutical formulations of camptothecins and process for making same